Safety evaluation of apremilast for the treatment of psoriasis

References

• Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314–320, review.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007 Jul;157(1):68–73.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat. 2010;18(4):297–304.
   PubMed Web of Science ®Google Scholar
• Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18-5.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker JH. Psoriasis. N Engl J Med. 2009;361:496–509.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Zhang S, Dattola A, et al. New insights into the pathogenesis of cutaneous autoimmune disorders. J Biol Regul Homeost Agents. 2012 Apr-Jun;26(2):165–170. Review
   PubMed Web of Science ®Google Scholar
• Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159:1092–1102.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis. Actas Dermosifiliogr. 2014;105:9–20.
   PubMedGoogle Scholar
• Arican O, Aral M, Sasmaz S, et al. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005 Oct 24;2005(5):273–279.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Caposiena D, Garofalo V, et al. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast. Expert Rev Clin Immunol. 2016;12(3):237–249.
   PubMed Web of Science ®Google Scholar
• Zambon AC, Zhang L, Minovitsky S, et al. Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. Proc Natl Acad Sci USA. 2005;102(24):8561–8566.
   PubMed Web of Science ®Google Scholar
• Tilg H, Trehu E, Atkins MB, et al. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994;83(1):113–118.
   PubMed Web of Science ®Google Scholar
• Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005;10:1503–1519.
   PubMed Web of Science ®Google Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–1590.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp K, Leonardi C, et al. Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: results from a phase III, randomized, controlled trial (ESTEEM 1) [poster]. Poster presented at: 72nd Annual Meeting of the American Academy of Dermatology (AAD); 2014 Mar 21–25; Denver, CO.
   Google Scholar
• Reich K, Sobell J, Day R, et al. Change in weight with apremilast, an oral phosphodiesterase 4 inhibitor: pooled analysis of the ESTEEM 1 and ESTEEM 2 trials. Poster. Presented at: the 73rd Annual Meeting of the American Academy of Dermatology; 2015 Mar 20–24; San Francisco, CA.
   Google Scholar
• Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387–1399.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Adebajo AO, Gladman DD, et al. Long-term (104-week) efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase III, randomized, controlled trial and open-label extension (palace 1). Presented at: the Summer Academy Meeting of the American Academy of Dermatology; 2015 Aug 19–23; New York, NY.
   Google Scholar
• Kavanaugh A, Mease PJ, Adebajo AO, et al. Long-term (52-week) results of a Phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis [abstract]. Proceedings of the 14th Annual European League Against Rheumatism (EULAR); 2013b June 12-15; Madrid, Spain: Abstract.
   Google Scholar
• Edwards CJ, Blanco FJ, Crowley J, et al. Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement (PALACE 3) [poster]. Poster presented at: 77th Annual Scientific Meeting of the American College of Rheumatology (ACR) and the 48th Annual Meeting of the Association of Rheumatology Health Professionals (ARHP); 2013b Oct 25-30; San Diego, CA, USA.
   Google Scholar
• Mease PJ, Kavanaugh A, Adebajo AO, et al. Laboratory abnormalities in patients with psoriatic arthritis receiving apremilast, an oral phosphodiesterase 4 inhibitor: pooled safety analysis of three phase 3, randomized, controlled trials [poster]. Poster presented at: 77th Annual Scientific Meeting of the American College of Rheumatology (ACR) and the 48th Annual Meeting of the Association of Rheumatology Health Professionals (ARHP); 2013a Oct 25-30; San Diego, CA, USA.
   Google Scholar
• Mease PJ, Kavanaugh A, Gladman D, et al. Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: pooled safety analysis of three phase 3, randomized, controlled trials [poster]. Poster presented at: 77th Annual Scientific Meeting of the American College of Rheumatology (ACR) and the 48th Annual Meeting of the Association of Rheumatology Health Professionals (ARHP); 2013b Oct 25-30; San Diego, CA, USA.
   Google Scholar
• Wells AF, Edwards CJ, Adebajo AO, et al. Apremilast in the treatment of DMARD-naive psoriatic arthritis patients: results of a phase 3 randomized, controlled trial (PALACE 4) [oral]. Oral presented at: 77th Annual Scientific Meeting of the American College of Rheumatology (ACR) and the 48th Annual Meeting of the Association of Rheumatology Health Professionals (ARHP); 2013 Oct 25-30; San Diego, CA USA.
   Google Scholar
• Papp K, Chen R, Day R, et al. Safety and tolerability of apremilast up to 182 weeks: pooled analyses from phase 3 clinical trials. Abstract 2347, presented at the 74th American Academy of Dermatology 2016 annual conference; 2016 Mar 7; Washington, DC.
   Google Scholar
• Papp KA, Reich K, Sobell JM, et al. Two-year safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: results from a Phase 3, randomized, controlled trial (ESTEEM 1). Presented at: the 73rd Annual Meeting of the American Academy of Dermatology; 2015 Mar 20-24; San Francisco, CA.
   Google Scholar
• Bianchi L, del Duca E, Romanelli M, et al. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis. Expert Opin Drug Metab Toxicol. 2016;12(9):1121–1128. doi:10.1080/17425255.2016.1206886.
   PubMed Web of Science ®Google Scholar
• Wu A, Scheffler M First-time-in-man safety/tolerability and pharmacokinetics of ascending oral doses of apremilast in healthy subjects [Poster]. Poster presented at: 71st Annual Meeting of the International Society for Investigative Dermatology (SID); 2011 May 4–7; Phoenix, AZ, USA.
   Google Scholar
• Assaf M, Laille E, Liu L, et al. Impact of hepatic impairment on the pharmacokinetics of apremilast and m12 metabolite [poster]. Poster presented at: 41st Annual Meeting of the American College of Clinical Pharmacology (ACCP); 2012 Sep 23–25; San Diego, CA, USA.
   Google Scholar
• Summit NJ. Otezla (apremilast) tablets [prescribing information]. Celgenen Corporation; 2014 Sep.
   Google Scholar
• Brullo C, Massa M, Villa C, et al. Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors. Bioorg Med Chem. 2015;23(13):3426–3435.
   PubMed Web of Science ®Google Scholar